Search research articles
Contact Us
Filters
Showing results (81-90 of 110) with videos related to
Page
of 11
Sort By:
The American Journal of Medicine
|
January 9, 2007
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms
Russell D Hull, Graham F Pineo, Rollin F Brant, et al.
The American Journal of Medicine
|
December 6, 2006
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer
Russell D Hull, Graham F Pineo, Rollin F Brant, et al.
Thrombosis Research
|
March 19, 2023
Low-dose immune tolerance induction therapy in severe hemophilia a children in China: Starting earlier resulted in better inhibitor eradication outcomes
Zhengping Li, Jie Sun, Zekun Li, et al.
Thrombosis Research
|
February 5, 2023
The efficacy of the rituximab-containing rescue-regimen for severe hemophilia A inhibitor children who relapsed following successful immune tolerance induction with rituximab in China
Zhengping Li, Zekun Li, Jie Sun, et al.
Thrombosis Research
|
March 2, 2023
The efficacy of sequential MMF-rescue-regimen to eradicate inhibitors for refractory severe hemophilia A inhibitor children in China
Zhengping Li, Zekun Li, Jie Sun, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
June 23, 2021
Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes
Haowei Linda Sun, Ming Yang, Man-Chiu Poon, et al.
Research and Practice in Thrombosis and Haemostasis
|
October 20, 2021
The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
Haowei Linda Sun, Ming Yang, Man-Chiu Poon, et al.
Pediatric Investigation
|
June 24, 2024
Low-dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor-titer below 200 BU/mL
Zhengping Li, Jie Sun, Zekun Li, et al.
Cerebrovascular Diseases (Basel, Switzerland)
|
November 20, 2013
Stroke prenotification is associated with shorter treatment times for warfarin-associated intracerebral hemorrhage
Dar Dowlatshahi, Jason K Wasserman, Ken S Butcher, et al.
Health and Quality of Life Outcomes
|
September 18, 2012
Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban China
Runhui Wu, Jishui Zhang, Koon Hung Luke, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 110) with videos related to
Sort By:
Page
of 11
The American Journal of Medicine
|
January 9, 2007
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms
Russell D Hull, Graham F Pineo, Rollin F Brant, et al.
The American Journal of Medicine
|
December 6, 2006
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer
Russell D Hull, Graham F Pineo, Rollin F Brant, et al.
Thrombosis Research
|
March 19, 2023
Low-dose immune tolerance induction therapy in severe hemophilia a children in China: Starting earlier resulted in better inhibitor eradication outcomes
Zhengping Li, Jie Sun, Zekun Li, et al.
Thrombosis Research
|
February 5, 2023
The efficacy of the rituximab-containing rescue-regimen for severe hemophilia A inhibitor children who relapsed following successful immune tolerance induction with rituximab in China
Zhengping Li, Zekun Li, Jie Sun, et al.
Thrombosis Research
|
March 2, 2023
The efficacy of sequential MMF-rescue-regimen to eradicate inhibitors for refractory severe hemophilia A inhibitor children in China
Zhengping Li, Zekun Li, Jie Sun, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
June 23, 2021
Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes
Haowei Linda Sun, Ming Yang, Man-Chiu Poon, et al.
Research and Practice in Thrombosis and Haemostasis
|
October 20, 2021
The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
Haowei Linda Sun, Ming Yang, Man-Chiu Poon, et al.
Pediatric Investigation
|
June 24, 2024
Low-dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor-titer below 200 BU/mL
Zhengping Li, Jie Sun, Zekun Li, et al.
Cerebrovascular Diseases (Basel, Switzerland)
|
November 20, 2013
Stroke prenotification is associated with shorter treatment times for warfarin-associated intracerebral hemorrhage
Dar Dowlatshahi, Jason K Wasserman, Ken S Butcher, et al.
Health and Quality of Life Outcomes
|
September 18, 2012
Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban China
Runhui Wu, Jishui Zhang, Koon Hung Luke, et al.
Page
of 11